GDC-0917

• CAT Number: I001716
• CAS Number: 1446182-94-0
• Molecular Formula: C₂₉H₃₆N₆O₄S
• Molecular Weight: 564.70
• Purity: ≥95%
• Target: IAP
• Solubility: DMSO: ≥ 61 mg/mL
• Storage: Store at -20℃
• IUPAC Name: (2S)-1-[(2S)-2-cyclohexyl-2-[[(2S)-2-(methylamino)propanoyl]amino]acetyl]-N-[2-(1,3-oxazol-2-yl)-4-phenyl-1,3-thiazol-5-yl]pyrrolidine-2-carboxamide
• InChI: InChI=1S/C29H36N6O4S/c1-18(30-2)24(36)32-23(20-12-7-4-8-13-20)29(38)35-16-9-14-21(35)25(37)34-27-22(19-10-5-3-6-11-19)33-28(40-27)26-31-15-17-39-26/h3,5-6,10-11,15,17-18,20-21,23,30H,4,7-9,12-14,16H2,1-2H3,(H,32,36)(H,34,37)/t18-,21?,23-/m0/s1
• InChIKey: HSHPBORBOJIXSQ-IAZWUMQMSA-N
• SMILES: CC(C(=O)NC(C1CCCCC1)C(=O)N2CCCC2C(=O)NC3=C(N=C(S3)C4=NC=CO4)C5=CC=CC=C5)NC

GDC-0917 (CAT: I001716) is an orally bioavailable small-molecule inhibitor of the inhibitor of apoptosis proteins (IAPs), including XIAP (X-linked inhibitor of apoptosis protein), cIAP1 (cellular inhibitor of apoptosis protein 1), and cIAP2 (cellular inhibitor of apoptosis protein 2). By inhibiting these proteins, GDC-0917 promotes apoptosis (programmed cell death) and has the potential to sensitize cancer cells to chemotherapy. It has shown efficacy in preclinical models of various cancers, including hematologic malignancies and solid tumors. GDC-0917 is being investigated in clinical trials for the treatment of advanced or refractory solid tumors and lymphomas.